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Abstract: Objective: To evaluate bone mineral density (BMD) in patients with ankylosing spondylitis 
(AS) and determine its correlation with the demographic and clinical characteristics of AS. Patients 
and Methods: Demographic, clinical and osteodensitometric data were evaluated in a cross-sectional 
study that included 136 patients with AS. Spine and hip BMD were measured by means of dual 
energy X-ray absorptiometry (DXA). Using the modified Schober’s test we assessed spine mobility. 
We examined the sacroiliac, anteroposterior and lateral dorso-lumbar spine radiographs in order to 
grade sacroiliitis and assess syndesmophytes. Disease activity was evaluated using C-reactive protein 
(CRP) levels and erythrocyte sedimentation rate (ESR). Demographic data and BMD measurements 
were compared with those of 167 age- and sex-matched healthy controls. Results: Patients with AS 
had a significantly lower BMD at the spine, femoral neck, trochanter and total hip as compared to 
age-matched controls (all p<0.01). According to the WHO classification, osteoporosis was present 
in 20.6% of the AS patients at the lumbar spine and in 14.6% at the femoral neck. There were no 
significant differences in BMD when comparing men and women with AS, except for trochanter 
BMD that was lower in female patients. No correlations were found between disease activity 
markers (ESR, CRP) and BMD. Femoral neck BMD was correlated with disease duration, 
Schober’s test and sacroiliitis grade. Conclusion: Patients with AS have a lower spine and hip BMD as 
compared to age- and sex-matched controls. Bone loss at the femoral neck is associated with 
disease duration and more severe AS. 
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Introduction 
Bone loss is now a widely acknowledged characteristic of many inflammatory rheumatic diseases 
[1]. Within the range of chronic inflammatory arthritis, ankylosing spondylitis (AS) - the 
prototypical disease of the seronegative spondyloarthropathies - raises the dilemma of a disease 
characterized by new bone formation occurring in parallel with a process of bone loss [2]. The 
disease predominantly affects young males and is associated with progressive functional 
impairment, increased work disability and decreased quality of life [3].   
Recent studies have shown that patients with ankylosing spondylitis display a high prevalence of 
OP and run a higher risk for fragility fractures [4]. However, the prevalence, distribution, severity 
and pathogenesis of osteoporosis in AS is still under debate. There are several factors possibly 
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involved in bone loss in rheumatic diseases, including reduced mobility due to functional 
impairment, adverse effects of some therapeutic agents, genetic factors, hormonal abnormalities 
and uncontrolled disease activity [5].  
In spite of the difficulties in assessing bone mineral density (BMD) due to progressive 
emergence of syndesmophytes, dual energy X-ray absorptiometry (DXA) is considered the best 
method for diagnosing osteoporosis in AS patients [6].  
The main objective of the present study was to evaluate bone mineral density (BMD) in 
ankylosing spondylitis patients, exploring the overall and subgroup incidence of reduced bone mass. 
The bone mineral density data from AS patients were compared with the data from a healthy age- 
and sex-matched population. We also evaluated the relationships between BMD and demographic 
and disease variables. 
Material and Method 
Patients and Methods 
In this cross-sectional study, 136 patients with AS in all stages of the disease were enrolled. They 
were selected from regular attendees of the Rheumatology Department with the University of 
Medicine and Pharmacy Cluj-Napoca, Romania. All patients had a primary AS diagnosis according 
to the modified New York criteria [7]. We excluded subjects with any condition or treatment that 
might have affected bone metabolism (malabsorption, chronic renal and liver diseases, thyroid 
diseases, alcoholism, corticosteroids, anticonvulsants) and patients with other forms of 
spondyloarthropathy.    
The control group consisted of 167 age- and sex-matched healthy subjects without a history of 
inflammatory rheumatic disease, conditions or medication responsible for bone loss.  
Demographic and clinical variables were recorded, including age, weight, height, body mass 
index (BMI = Weight/Height2, kg/m2), disease duration, peripheral arthritis, coxitis and uveitis. 
Disease duration was defined as the time elapsed between the onset of the specific disease 
manifestations and enrolment in the study. Spine mobility was assessed using the modified 
Schober’s test. We have also recorded the patients’ medication history including intermittent or 
continuous use of non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying drugs 
(DMARDs) and tumour necrosis factor-alpha (TNFα) blockers (Infliximab, Etanercept and 
Adalimumab). Sacroiliac, anteroposterior and lateral dorso-lumbar spine radiographs were 
examined in order to grade the sacroiliitis (according to New York criteria) and assess the   
syndesmophytes.  
Bone mineral density (BMD) was measured at the postero-anterior (PA) lumbar spine (L2-L4), 
femoral neck, and total hip by means of dual energy X-ray absorptiometry (DXA), using a Lunar 
Prodigy Advance (GE Healthcare, USA). The same densitometer of the same centre (Centre of 
Osteoarthrology "Osart" Cluj Napoca, Romania) was used for all BMD measurements. Results 
were expressed as BMD in g/cm2, and also as T-score (standard deviation from peak adult BMD) 
and Z-score (standard deviation from age-matched BMD). According to the WHO criteria, 
osteopenia was defined as T-score between -1 and -2,5 and osteoporosis as a T-score below -2,5 [8]. 
Statistical Analysis 
The statistical programs Epi-Info 6 and SPSS were used for statistical analysis. Results were 
expressed as mean (standard deviation), or number (percentage). The Student’s t-test was used to 
compare continuous variables between AS patients and controls, and between subgroups of AS 
patients. The chi-square test for the categorical variables or the Kruskal-Wallis test was performed 
when appropriate. The correlations between variables were presented as the Spearman’s correlation 
coefficient (rho). The level of statistical significance was < 0.05 (2-tailed). 
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Results 
The demographic, clinical, radiological and laboratory characteristics of the patient group are 
listed in table 1. Ninety-eight per cent of the patients were receiving intermittent or continuous 
treatment with NSAIDs and 78% of the patients were also treated with at least one disease-
modifying drug (sulphasalazine, methotrexate and leflunomide). Ten patients were given a blocker 
of tumour necrosis factor α (Infliximab, Etanercept and Adalimumab). 
Table 1. Clinical, radiological and laboratory characteristics of patients with ankylosing spondylitis 
(n =136) 
Variables  Mean (SD) or n (%) Median (range) 
Age (years)  45.7 (14.0)  46.3 (21.4 – 86.7) 
Male/Female [n (%)]    99 (72,8)/37 (27.2)   
Disease duration (years), (n = 132)
∗   14.3 (10.1)  12 (6 months – 44 years) 
Peripheral arthritis [n (%)], (n = 127)
∗  66 (52)   
Coxitis [n (%)], (n =132)
∗  20 (15.2)   
Uveitis [n (%)],  (n = 125)
∗  33 (26.4)   
Schober’s test (cm), (n = 126)
∗    2.2 (1.7)  2 (0 - 6) 
Sacroiliitis: grade 2, [n (%)] 
                  grade 3 or 4 
48 (35.3) 
88 (64.7) 
 
Syndesmophytes [n (%)], (n = 115)
∗  45 (39.1)   
ESR (mm/hour), (n = 122)
∗    34.8 (28.7)  28 (2-120) 
CRP (mg/dl), (n = 115) 
∗  1.7 (2.4)  1 (0-16) 
Data presented as mean (standard deviation), median (range: min-max) or numbers (percentage) of patients 
*Number of patients varies from 136 due to missing data 
BMI: body mass index; ESR: erythrocyte sedimentation rate;  
CRP: C-reactive protein; DMARDs: disease-modifying drugs 
 
The healthy control subjects were age- and sex-matched to the patients with AS (Table 2). 
Patients with AS displayed a significantly lower weight and height than the subjects in the control 
group, but BMI was similar in both groups (p = 0.11; Table 2).  
 The femoral neck BMD and total hip BMD were lower in patients with AS as compared to 
controls, and the differences were highly significant (both p < 0.0001; Table 2). Similar results were 
observed for T- and Z-score of the neck and total hip. Lumbar spine BMD was significantly lower 
in the AS group as compared to healthy controls. The corresponding T- and Z-score were also 
decreased in AS patients, although the difference did not reach significance (both p > 0.10; Table 
2).  
According to the WHO classification for the lumbar spine BMD, 28 (20.6%) AS patients were 
osteoporotic and 45 (33.1%) were osteopenic (controls: 1.8% and 37.4%, respectively). At the 
femoral neck and total hip, 19 patients (14.6%) and 12 (9.2%), respectively were osteoporotic 
(controls: 1.2% at both sites). In addition, 58 (44.6%) patients were osteopenic at the femoral neck 
and 54 (41.5%) at the total hip. Significantly more patients with AS were osteopenic at the total hip 
or osteoporotic at the lumbar spine, femoral neck and total hip (p < 0.001).  
The study included 37 women with AS, (16 pre-menopausal and 21 postmenopausal), with the 
mean age of 47.7 (12.5) years. The demographic variables (age, weight, BMI, menopausal status) 
were similar in the case of the women with AS and those from the control group. In the pre-
menopausal group, BMD at any measured site were similar between women with AS and controls, 
except the trochanter BMD (AS vs. controls: [0.75 (0.1)] vs. [0.84 (0.1)] g/cm2; p = 0.01). In 
contrast, postmenopausal women with AS had a significantly lower BMD at the femoral neck, 
trochanter and total hip as compared to controls (all p < 0.01). There was no significant difference 
between the 2 groups at the lumbar spine (postmenopausal women with AS vs. controls: [1.05 
(0.2)] vs. [1.10 (0.2)] g/cm2; p = 0.35). 
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Table 2. Comparative demographic and osteodensitometric variables of ankylosing spondylitis 
(AS) patients and controlsa 
  AS (n = 136)  Controls (n = 167)  Pb 
Demographic varibles 
   Age (years) 
 
45.7 (14.0) 
 
46.9 (12.9) 
 
0.44  
  Sex [%, (95% CI)] 
    Males 
    Females 
 
72.8 (64.5 – 80.1) 
27.2 (19.9 -35.5) 
 
61.7 (53.8 – 69.1) 
38.3 (30.9 – 46.2) 
 
NSc 
  Weight (kg)  71.7 (14.7) 76.6  (15.3)  0.005 
  Height (cm)  167.9 (9.3) 170.5  (10.0)  0.02 
  BMI (kg/m2)  25.4 (4.8)  26.3 (4.8)  0.11 
DXA variables  
  L2-L4 BMD (g/cm2) 
  T-score L2-L4 
  Z-score L2-L4 
 
1.109 (0.21) 
-1.0 (1.7) 
-0.9 (1.8) 
 
1.167 (0.17) 
-0.9 (1.5) 
-0.4 (1.5) 
 
0.04  
0.44  
0.11  
  Left femoral neck BMD (g/cm2) 
  T-score femoral neck 
  Z-score femoral neck   
0.911 (0.16) 
-1.1 (1.2) 
-0.7 (1.8) 
0.986 (0.16) 
-0.5 (1.2) 
0.1 (1.0) 
< 0.0001 
< 0.0001 
< 0.0001 
  Trochanter BMD(g/cm2) 
  T-score trochanter 
  Z-score trochanter 
0.769 (0.15) 
-1.2 (1.3) 
-0.9 (1.3) 
0.842 (0.14) 
0.5 (1.1) 
-0.1 (1.1) 
< 0.0001 
< 0.0001 
< 0.0001 
  Total hip (g/cm2) 
  T-score total hip 
  Z-score total hip 
0.938 (0.16) 
-0.9 (1.1) 
-0.6 (1.2) 
1.026 (0.15) 
-0.3 (1.0) 
0.1 (1.1) 
< 0.0001 
< 0.0001 
< 0.0001 
a Data presented as mean (standard deviation), except where noted otherwise  
b Student’s t-test  
c Overlap of the 95% CI of the frequency was considered to be not significant (NS) 
BMI: body mass index; DXA: dual energy X-ray absorptiometry; BMD: bone mineral density; 
T-score: standard deviation below peak bone mass; Z-score: standard deviation below the mean BMD for people of the same age
 
Ninety-nine men with mean disease duration of 44.9 (13.0) years and mean disease duration of 
14.1 (9.8) years were compared to 103 age-matched healthy men. Men with AS displayed a 
significantly lower weight [AS vs. controls: 73.1 (14.1) vs. 81.2 (13.7) kg; p < 0.0001] and height [AS 
vs. controls: 171.2 (7.5) vs. 176.1 (13.7) cm; p < 0.0001] than subjects in the control group. The 
lumbar spine, femoral neck, trochanter and total hip BMD were significantly lower in men with AS 
as compared with the controls (all p < 0.01). 
Table 3 illustrates the comparison between males and females in the study group. Females with 
AS had a significantly lower weight, height and BMI as compared with males patients. Both sexes 
were well matched in terms of age and disease duration, but differed with regard to disease severity. 
Male patients displayed notably reduced spine mobility and a more severe sacroiliitis. They also had 
a more active disease, as illustrated by the increased occurrence of peripheral joint involvement and 
higher CRP values as compared to female patients. BMD at the lumbar spine, femoral neck and 
total hip were similar in women and men with AS (p > 0.05). In contrast, trochanter BMD was 
significantly lower in female patients with AS as compared to male patients (p = 0.002, Table 3). 
Men with AS were more likely to suffer from osteoporosis than the females but the difference were 
not statistically significant [28.3% (19.7-38.2)] vs. [24.3% (11.8-41.2)]. 
There was a mild positive correlation between weight and bone density measured at any site 
(rho ranging from 0.25 to 0.39; all p < 0.01). Also, BMI was correlated with the lumbar spine, 
trochanter and total hip BMD, but not with the femoral neck BMD. There was a significant 
negative correlation between disease duration and BMD at the femoral neck and total hip (rho = -
0.28, and rho = - 0.21, respectively; both p < 0.01). There was no correlation between the lumbar 
spine BMD and disease duration. Only femoral neck BMD was correlated with age (rho = -0.21, p 
= 0.02). Also, femoral neck BMD was correlated with Schober’s test (rho = 0.28, p < 0.01) and 
sacroiliitis grade (rho = - 0.19, p < 0.05), while lumbar spine BMD was not. We found no 
correlation between BMD at any site and disease activity parameters (ESR, CRP or BASDAI) (all p 
> 0.05). MUNTEAN Laura, ŢIGAN Ştefan, SIMON Siao-Pin, BOLOŞIU Călin, ŞTEFAN Simona, PETCU Ana et al.  
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Table 3. Demographic, clinical, radiological and laboratory characteristics of women and men with 
ankylosing spondylitis (AS) 
Women with SA  Men with SA  Variables 
n*  Mean (SD) or n (%)  n*  Mean (SD) or n (%) 
p 
Demographic varibles 
 Age (years) 
 
37 
 
47.7 (12.5) 
 
99
 
44.9 (13.0) 
 
0.26a  
 Weight (kg)  37  68.1 (15.9) 99 73.1  (14.1)  0.08a 
 Height (cm)  37  159.1 (7.8)  99 171,2 (7,5)  < 0.0001a 
 BMI (kg/m2)  37  26.9 (5.5)  99 24.9 (4.4)  0.03a  
Disease variables 
 Disease duration (years)  
 
35 
 
5.1 (11.0) 
 
97
 
14.1 (9.8) 
 
0.60a  
 Peripheral arthritis [n (%)] 34 8  (23.5) 93 40 (43.0)  0.002b  
 Coxitis [n (%)]  35  3 (8.6)  97 17 (17.5)  0.32b  
 Uveitis [n (%)]  34  9 (26.5) 91 24  (26.4) 0.82b  
 Schober’s test (cm)  34  3.1 (1.9)  92 1.9 (1.6)  0.001a  
 Sacroiliitis grade [median (range)]  37  2 (2-4)  99 3 (2-4)  0.02b  
 Syndesmophytes [n (%)]  28  7 (25)  87 38 (43.7)  0.12b  
 ESR (mm/hour)    34  35.7 (27.7) 88 34.4  (29.2)  0.82a  
 CRP (mg/dl)  32  1.4 (3.0)  82 1.8 (2.1)  0.03c  
DXA variables  
 Lumbar spine BMD (g/cm2)   
 
37 
 
1.09 (0.2) 
 
99
 
1.11 (0.2) 
 
0.60a  
 Left femoral neck (g/cm2)    37  0.88 (0.2)  93 0.92 (0.2)  0.18a  
 Trochanter BMD (g/cm2)  37  0.71 (0.1)  93 0.79 (0.2)  0.002a  
 Total hip (g/cm2)  37  0.90 (0.1)  93 0.95 (0.2)  0.08a  
Data presented as mean (standard deviation) except where noted otherwise  
 a Student’s t-test 
bχ2 test 
c Mann-Whitney U test 
*Number of patients varies from n = 37 females and n = 99 males due to missing data 
BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DXA: dual energy X-ray absorptiometry; BMD: 
bone mineral density.   
Discussion 
The results of the cross-sectional study exploring the BMD at different measurement sites and 
the incidence of reduced BMD revealed that patients with AS had lower bone mass than healthy 
age- and sex-matched controls. Further analysis demonstrated that femoral neck BMD was 
correlated with demographic and disease variables that reflected the cumulative damage of AS. In 
contrast, no correlation was found between BMD at any site and disease activity variables. 
Our results agreed with previous studies that demonstrated lower BMD in AS patients [9-11]. 
Bone loss was noticeable early in the course of the disease, at all measurement sites. In contrast, 
lumbar spine BMD values were similar or even increased in AS patients with advanced disease, as 
compared to controls. It was suggested that in late AS, the presence of syndesmophytes could 
falsely elevate the spine BMD values [9,10]. In contrast to the aforementioned studies, we did not 
find a significant increase in bone mass at the lumbar spine. This might be explained by the 
heterogeneity of the studied population, since we have included AS patients in all stages of the 
disease, and more than half of the patients did not have syndesmophytes. In a recent study on a 
cohort of 103 patients with AS, Karberg et al [12] reported that bone loss was more frequently 
detected in AS patients with syndesmophytes, suggesting that bone growth and bone loss occurred 
in parallel. Their conclusion was that “the method of bone density measurement is critical and 
should be different depending on disease duration”. It was established that DEXA at the femoral 
neck was the most sensitive method for evaluating OP in AS, even in patients without 
syndesmophytes.  
The WHO criteria for the OP diagnosis have been validated for postmenopausal white women, 
while AS is a systemic disease mainly affecting male subjects. However, fracture risk is associated 
with a T score less than -2.5 SD in both sexes, and therefore it is reasonable to accept this Bone Mineral Density in Patients with Ankylosing Spondylitis: Frequencies and Relations with Demographic 
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classification in the absence of validated values in AS patients. In our study, we found an increased 
prevalence of osteoporosis at the lumbar spine and femoral neck (20.6% and 14.6%, respectively). 
These results were consistent with the reported prevalence of osteoporosis in AS varying from 
18.7% to 62% [4].  
Our study confirmed the presence of a significant bone loss at the proximal femur (femoral 
neck, trochanter, total hip) only in postmenopausal women. In our patients, pre-menopausal 
women had a small, but significant decrease of trochanter BMD. We had also shown that women 
with AS at any age had similar spine BMD values with controls, results that agreed with previous 
studies. Juanola et al. [13] did not find significant variation in BMD values between pre-menopausal 
women with AS and controls. In contrast, in Speden’s report, which included 66 women with AS, 
both pre-and postmenopausal patients had a significantly lower BMD at the proximal femur, as 
compared to their age and sex-matched controls [14].  
The present study also demonstrated a consistent, statistically significant BMD decrease at all 
measurement sites in males with AS, as compared to age-matched healthy controls. In contrast, 
Franck et al. [15], examining 190 males with AS, had demonstrated a significant BMD reduction in 
AS patients’ group only in the femoral neck and total hip.   
The differences between males and females with AS have been examined by several researches 
and the results they yielded were quite conflicting. Some researchers found that male patients were 
prone to both more severe disease and osteoporosis [9,16], while others could not find any 
difference between BMD values of men and women [10,11]. In our study, BMD values were similar 
in case of both men and women, except for trochanter BMD. When applying the WHO criteria, we 
could not find any significant difference in what concerned the incidence of osteoporosis in men 
and women with AS. Our results therefore suggested that AS eliminates the relative protection of 
male patients against osteoporosis.  
We found a significant negative correlation between disease duration and BMD at the femoral 
neck and total hip. Similarly, Toussirot et al. [17], who worked on a cohort of 71 patients with early 
disease, showed that only the femoral neck was correlated with disease duration. In addition, Capaci 
et al. [11] demonstrated a significant positive correlation between disease duration and lumbar spine 
BMD. The lack of correlation between BMD at any site and disease activity parameters (ESR, CRP) 
agreed with some previous studies [17], whereas it was in contrast with several others [18]. 
However, in a cross sectional study it is difficult to establish a correlation between a biological 
marker measured at a given point and BMD, which is a parameter reflecting the cumulative 
influence of the disease [2]. In the present study, femoral neck BMD was correlated with 
parameters reflecting the cumulative damage of AS (Schober’s test, sacroiliitis grade), not with 
markers of disease activity. The results suggested that bone loss in AS may involve different 
mechanisms at different stages of the disease. 
Acknowledgements 
The authors would like to acknowledge the technical support provided by Livia Otoiu and 
“Osart" Osteoarthrology Centre of Cluj Napoca, Romania. 
References 
1.  Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of 
inflammation on bone. Immunol Rev 2005;208:228-251. 
2.  Wendling D. Bone loss in ankylosing spondylitis: Can we put the puzzle together ?. J 
Rheumatol 2005;32:1184-1186. 
3.  Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann 
Rheum Dis 2002;61 (Suppl 3):iii8 –iii18. 
4.  Bessant R, Keat A. How should clinicians manage osteoporosis in ankylosing spondylitis? J 
Rheumatol 2002;29:1511-1519. MUNTEAN Laura, ŢIGAN Ştefan, SIMON Siao-Pin, BOLOŞIU Călin, ŞTEFAN Simona, PETCU Ana et al.  
 
90 
5.  Toussirot E, Wendling D. Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 
2000;18(Suppl 21):S16-S20. 
6.  Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing 
spondylitis. Curr Opin Rheumatol 2007;19:335-339. 
7.  Van Der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing 
spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 
1984;27:361-368. 
8.  World Health Organization. Assessment of fracture risk and its application to screening for 
postmenopausal osteoporosis. WHO Technical Report Series 843. Geneva: WHO, 1994. 
9.  Donnelly S, Doyle DV, Denton A, et al. Bone mineral density and vertebral compression 
fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994;53:117-121. 
10.  Mulaji AB, Upadhyay SS, Ho EKW. Bone mineral density in ankylosing spondylitis. DEXA 
comparison of control subjects with mild and advanced cases. J Bone Joint Surg Br 
1994;76:660-665. 
11.  Capaci K, Hepguler S, Argin M, et al. Bone mineral density in mild and advanced ankylosing 
spondylitis. Yonsei Med J  2003;44:379-384. 
12.  Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently 
in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005;32:1290-1298. 
13.  Juanola X, Mateo L, Nolla JM, Roig-Vilaseca D, Campoy E, Roig-Escofet D. Bone mineral 
density in women with ankylosing spondylitis. J Rheumatol 2000;27(4):1028-1031. 
14.  Speden DJ, Calin AI, Ring FJ, Bhalla AK. Bone mineral density, calcanean ultrasound, and 
bone turnover markers in women with ankylosing spondylitis. J Rheumatol  2002;29:516-521. 
15.  Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, 
biochemical markers of bone metabolism, and osteoprotegerin serum levels in ankylosing 
spondylitis. J Rheumatol 2004;31:2236-2241. 
16.  Devogelaer JP, Maldague B, Malghem J, et al. Appendicular and vertebral bone mass in 
ankylosing spondylitis. A comparison of plain radiographs with single- and dual-photon 
absorptiometry and with quantitative computed tomography. Arthritis Rheum 1992;35:1062-
1067. 
17.  T o u s s i r o t  E ,  M i c h e l   F ,  W e n d l i n g  D .  B o n e  density, ultrasound measurements and body 
composition in early ankylosing spondylitis. J Rheumatol 2001;40:882-888. 
18.  Kim HR, Kim HY, Lee SH.  Elevated serum levels of soluble receptor activator of nuclear 
factor kappa B ligand (sRANKL) and reduced bone mineral density in patients with ankylosing 
spondylitis. Rheumatology 2006;45:1197-1200. 
© 2009 by the authors; licensee SRIMA, Cluj-Napoca, Romania. 